Top

Infection

Published in:

01-06-2016 | Editorial

Blue sky and some shadows: new antibiotics and new superbugs

The ECCMID 2016 in Amsterdam

Author: Johannes R. Bogner

Published in: Infection | Issue 3/2016

Excerpt

What is the latest news in infectious diseases and clinical microbiology? This question is so important for about 11,000 physicians, researchers, developers and also for the diagnostic and pharmaceutical industry from almost all countries on this planet that they travel to the place where they can see it all at once: about 3000 scientific contributions in oral presentations, posters and e-posters. For many, the focuses of interest were two topics: the spread of resistant organisms including what can be done against it and the development of new antibacterials. …

Liu YY, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16:161–8.CrossRefPubMed

Zurfuh K, et al. Occurrence of the plasmid-borne mcr-1 colistin resistance gene in extended-spectrum-beta-lactamase-producing Enterobacteriaceae in river water and imported vegetable samples in Switzerland. Antimicrob Agents Chemother. 2016;60:2594–5.CrossRefPubMed

Jung N, Lehmann C, Fatkenheuer G The “choosing wisely”: initiative in infectious diseases. Infection. 2015.

Kern WV. New antibacterial agents on the market and in the pipeline. Internist (Berl). 2015;56:1255–63.CrossRef

Draenert R, et al. Novel antibiotics: are we still in the pre-post-antibiotic era? Infection. 2015;43:145–51.CrossRefPubMedPubMedCentral

Heizmann WR, et al. Clinical efficacy of tigecycline used as monotherapy or in combination regimens for complicated infections with documented involvement of multiresistant bacteria. Infection. 2015;43:37–43.CrossRefPubMedPubMedCentral

Title: Blue sky and some shadows: new antibiotics and new superbugs
The ECCMID 2016 in Amsterdam
Author: Johannes R. Bogner
Publication date: 01-06-2016
Publisher: Springer Berlin Heidelberg
Published in: Infection / Issue 3/2016
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI: https://doi.org/10.1007/s15010-016-0898-7

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Blue sky and some shadows: new antibiotics and new superbugs

The ECCMID 2016 in Amsterdam

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2016

Documented cutaneous loxoscelism in the south of France: an unrecognized condition causing delay in diagnosis

Treatment of Pneumocystis pneumonia with intermediate-dose and step-down to low-dose trimethoprim–sulfamethoxazole: lessons from an observational cohort study

Refractory tenosynovitis with ‘rice bodies’ in the hand due to Mycobacterium intracellulare

Transitory ventricular tachycardia associated with influenza A infection of cardiac conduction tissue

Combination antibiotic therapy for the treatment of infective endocarditis due to enterococci

Implementing an intensified antibiotic stewardship programme targeting daptomycin use in orthopaedic surgery: a cost–benefit analysis from the hospital perspective

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page